Literature DB >> 9188923

Serum eosinophil peroxidase (EPO) levels in asthmatic patients.

M L Sanz1, A Parra, I Prieto, I Diéguez, A K Oehling.   

Abstract

Eosinophil granular proteins are a useful eosinophilic activation marker in asthmatic patients. In this study, the eosinophil peroxidase (EPO) levels were assessed in different stages of bronchial asthma, in 123 patients suffering from asthma, classified as mild (n =49), moderate (n = 49), and severe (n = 25), according to the International Consensus Report of Diagnosis and Treatment of Asthma, as well as in 27 healthy controls, with the aim of evaluating the importance of this protein as a severity marker in bronchial asthma, and its possible correlation with parameters such as anamnesis, respiratory function tests, and peripheral blood eosinophil count, and also with some allergologic diagnostic tests, both in vivo and in vitro. The geometric mean serum level of EPO was 9.3 +/- 11.3 ng/ml (median +/- SD) in controls, 28 +/- 37.8 ng/ml in the asthmatic patients. Depending on the asthma severity, the EPO levels were 25 +/- 30.5; 29 +/- 37.1, and 41 +/- 47.3 ng/ml in mild, moderate, and severe asthmatics, respectively, being the significant differences between the group of patients with mild and severe asthma (P < 0.001). The number of eosinophils (eos) in peripheral blood was 157 +/- 20 eos/mm3 in the controls, 334/35 eos/mm3 in mild asthmatics, 510 +/- 87 eos/mm3 in moderate asthmatics, and 658 +/- 72 eos/mm3 in severe asthmatics, with significant differences between all groups (from P < 0.05 to P < 0.001). Both the serum levels of EPO and the number of eosinophils were greater in patients with active asthma patients with inactive asthma (P < 0.001). Significant negative correlations (P < 0.001) were found between serum levels of EPO and FEV1 (rs = 0.30), MEF25-75 (rs = -0.33) and MEF50 (rs = -0.34), and a good positive correlation (rs = 0.80, P < 0.001) was found between EPO levels and the number of eosinophils in peripheral blood. We also found a significant positive correlation between eosinophil number and clinical score (rs = 0.54, P < 0.001) and between EPO levels and the mentioned score (rs = 0.46, P < 0.001).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188923     DOI: 10.1111/j.1398-9995.1997.tb01021.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  10 in total

1.  IL-17RB+ granulocytes are associated with airflow obstruction in asthma.

Authors:  Lin Li; Nicholas W Lukacs; Matthew A Schaller; Bryan Petersen; Alan P Baptist
Journal:  Ann Allergy Asthma Immunol       Date:  2016-12       Impact factor: 6.347

Review 2.  New Insights in Oxidant Biology in Asthma.

Authors:  Serpil C Erzurum
Journal:  Ann Am Thorac Soc       Date:  2016-03

3.  Correlation of systemic superoxide dismutase deficiency to airflow obstruction in asthma.

Authors:  Suzy A A Comhair; Kristin S Ricci; Mercedes Arroliga; Abigail R Lara; Raed A Dweik; Wei Song; Stanley L Hazen; Eugene R Bleecker; William W Busse; Kian Fan Chung; Benjamin Gaston; Annette Hastie; Mark Hew; Nizar Jarjour; Wendy Moore; Stephen Peters; W Gerald Teague; Sally E Wenzel; Serpil C Erzurum
Journal:  Am J Respir Crit Care Med       Date:  2005-05-05       Impact factor: 21.405

4.  Per a 5-derived T-cell peptides modulate NF-kB signalling to ameliorate allergic inflammation systemically in murine model of cockroach allergic hyper-reactivity.

Authors:  Swati Sharma; Ekta Nagar; Naveen Arora
Journal:  Clin Exp Immunol       Date:  2022-06-23       Impact factor: 5.732

5.  Cannabinoid receptor 2 augments eosinophil responsiveness and aggravates allergen-induced pulmonary inflammation in mice.

Authors:  R B Frei; P Luschnig; G P Parzmair; M Peinhaupt; S Schranz; A Fauland; C E Wheelock; A Heinemann; E M Sturm
Journal:  Allergy       Date:  2016-03-16       Impact factor: 13.146

6.  Respiratory syncytial virus increases eosinophil extracellular traps in a murine model of asthma.

Authors:  Josiane Silva Silveira; Géssica Luana Antunes; Rodrigo Benedetti Gassen; Ricardo Vaz Breda; Renato Tetelbom Stein; Paulo Márcio Pitrez; Aline Andrea da Cunha
Journal:  Asia Pac Allergy       Date:  2019-10-14

Review 7.  Asthma and Allergy: Unravelling a Tangled Relationship with a Focus on New Biomarkers and Treatment.

Authors:  Pablo Rodriguez Del Rio; Andrew H Liu; Magnus P Borres; Eva Södergren; Fabio Iachetti; Thomas B Casale
Journal:  Int J Mol Sci       Date:  2022-03-31       Impact factor: 5.923

Review 8.  Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice.

Authors:  Konstantinos Porpodis; Ioanna Tsiouprou; Apostolos Apostolopoulos; Polyxeni Ntontsi; Evangelia Fouka; Despoina Papakosta; Harissios Vliagoftis; Kalliopi Domvri
Journal:  J Pers Med       Date:  2022-06-30

9.  Biomarkers of Type 2 Airway Inflammation as Predictors of Loss of Asthma Control During Step-Down Therapy for Well-Controlled Disease: The Long-Acting Beta-Agonist Step-Down Study (LASST).

Authors:  Sonali Bose; Christian Bime; Robert J Henderson; Kathryn V Blake; Mario Castro; Emily DiMango; Nicola A Hanania; Janet T Holbrook; Charles G Irvin; Monica Kraft; Stephen P Peters; Joan Reibman; Elizabeth A Sugar; Kaharu Sumino; Robert A Wise; Linda Rogers
Journal:  J Allergy Clin Immunol Pract       Date:  2020-07-18

10.  The phylogeny of the mammalian heme peroxidases and the evolution of their diverse functions.

Authors:  Noeleen B Loughran; Brendan O'Connor; Ciarán O'Fágáin; Mary J O'Connell
Journal:  BMC Evol Biol       Date:  2008-03-27       Impact factor: 3.260

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.